BRITISH COLUMBIA, Canada--(BUSINESS WIRE)--InNexus Biotechnology Inc. (TSX VENTURE: IXS) (OTCBB: IXSBF), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL™) technology, today announced that Dr. Thomas Kindt, prestigious biomedical researcher and author, has joined InNexus’ newly formed Scientific Advisory Board, chaired by Dr. J. Donald Capra, President Emeritus of the Oklahoma Medical Research Foundation.
